Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKANNASDAQ:ALBTNASDAQ:OMGANASDAQ:PMCB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$1.25+3.3%$1.23$0.93▼$6.78$1.78M1.51213,160 shs4,267 shsALBTAvalon GloboCare$3.66-2.1%$4.01$2.11▼$21.60$6.93M0.16520,744 shs6,526 shsOMGAOmega Therapeutics$0.13-21.8%$0.12$0.10▼$2.63$6.92M1.653.15 million shs4.81 million shsPMCBPharmaCyte Biotech$1.07+5.9%$1.18$1.00▼$2.42$7.34M-0.4321,840 shs22,486 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda+3.31%+0.81%+8.70%-25.16%-82.24%ALBTAvalon GloboCare-2.27%-3.17%-9.63%-50.25%-18.96%OMGAOmega Therapeutics0.00%0.00%0.00%0.00%-94.08%PMCBPharmaCyte Biotech+5.92%+2.88%-17.05%-38.86%-47.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKANAkandaN/AN/AN/AN/AN/AN/AN/AN/AALBTAvalon GloboCare2.0754 of 5 stars0.05.00.04.32.91.70.0OMGAOmega Therapeutics2.3233 of 5 stars3.40.00.00.02.01.71.3PMCBPharmaCyte Biotech2.0491 of 5 stars0.05.00.00.02.50.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKANAkanda 0.00N/AN/AN/AALBTAvalon GloboCare 0.00N/AN/AN/AOMGAOmega Therapeutics 2.80Moderate Buy$9.207,260.00% UpsidePMCBPharmaCyte Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKANAkanda$836.66K2.13N/AN/A($76.10) per share-0.02ALBTAvalon GloboCare$1.37M5.07N/AN/A($17.22) per share-0.21OMGAOmega Therapeutics$8.10M0.85N/AN/A$1.05 per share0.12PMCBPharmaCyte BiotechN/AN/AN/AN/A$3.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKANAkanda-$32.28MN/A0.00∞N/AN/AN/AN/AN/AALBTAvalon GloboCare-$16.71M-$19.96N/A∞N/A-1,125.59%N/A-73.69%5/29/2025 (Estimated)OMGAOmega Therapeutics-$97.43M-$1.33N/AN/AN/A-902.93%-213.13%-41.24%6/20/2025 (Estimated)PMCBPharmaCyte Biotech$330K$0.742.02∞N/AN/A0.76%0.45%8/11/2025 (Estimated)Latest AKAN, ALBT, PMCB, and OMGA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALBTAvalon GloboCareN/A-$1.43N/A-$1.43N/AN/A3/17/2025Q3 2025PMCBPharmaCyte BiotechN/A-$0.10N/A-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKANAkandaN/AN/AN/AN/AN/AALBTAvalon GloboCareN/AN/AN/AN/AN/AOMGAOmega TherapeuticsN/AN/AN/AN/AN/APMCBPharmaCyte BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKANAkandaN/A1.41N/AALBTAvalon GloboCareN/A0.110.11OMGAOmega Therapeutics1.001.611.61PMCBPharmaCyte BiotechN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKANAkanda1.00%ALBTAvalon GloboCare1.42%OMGAOmega Therapeutics97.47%PMCBPharmaCyte Biotech34.24%Insider OwnershipCompanyInsider OwnershipAKANAkanda20.39%ALBTAvalon GloboCare37.30%OMGAOmega Therapeutics8.50%PMCBPharmaCyte Biotech10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKANAkanda1101.43 million1.14 millionNot OptionableALBTAvalon GloboCare51.89 million686,000Not OptionableOMGAOmega Therapeutics12055.37 million50.66 millionOptionablePMCBPharmaCyte Biotech46.86 million6.90 millionOptionableAKAN, ALBT, PMCB, and OMGA HeadlinesRecent News About These CompaniesMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 18, 2023 | msn.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 15, 2023 | finance.yahoo.comPharmaCyte Biotech Inc PMCBDecember 5, 2023 | morningstar.comWith biotech in a slump, the industry’s job market is upside downNovember 28, 2023 | statnews.comThe return of biotech’s “bump factor” amid an economic downturnNovember 24, 2023 | statnews.comPharmaCyte Biotech: Entry Into A Material Definitive Agreement, Other Events, Financial Statements And ExhibitsNovember 18, 2023 | cbonds.comPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | markets.businessinsider.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechNovember 15, 2023 | finance.yahoo.comBiotech power broker John Maraganore offers advice to the next crop of entrepreneursOctober 23, 2023 | statnews.comPharmaCyte completes tender offer to purchase sharesJune 15, 2023 | msn.comPharmaCyte Biotech Announces Final Results of Tender OfferJune 15, 2023 | finance.yahoo.comLos Angeles Biotech NewsJune 14, 2023 | bizjournals.comPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per ShareMay 11, 2023 | finance.yahoo.comBiotech ETFs’ Performance Deserves A LookApril 21, 2023 | nasdaq.com300 biotech and pharma CEOs including the head of Pfizer call for a reversal of the abortion pill banApril 12, 2023 | fortune.comHow DFW Becomes a Biotech HubApril 9, 2023 | dmagazine.comA 45-year-old biotech CEO may have reduced his biological age by at least 5 years through a rigorous medical program that can cost up to $2 million a year, Bloomberg reportedFebruary 2, 2023 | msn.comPharmaCyte Biotech to Implement Second $10-Million Share Repurchase PlanFebruary 2, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKAN, ALBT, PMCB, and OMGA Company DescriptionsAkanda NASDAQ:AKAN$1.25 +0.04 (+3.31%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$1.25 0.00 (-0.40%) As of 05/28/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.Avalon GloboCare NASDAQ:ALBT$3.66 -0.08 (-2.14%) Closing price 05/28/2025 03:58 PM EasternExtended Trading$3.70 +0.03 (+0.96%) As of 05/28/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Omega Therapeutics NASDAQ:OMGA$0.12 -0.03 (-21.83%) Closing price 02/24/2025Extended Trading$0.12 0.00 (0.00%) As of 02/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.PharmaCyte Biotech NASDAQ:PMCB$1.07 +0.06 (+5.92%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$1.05 -0.02 (-2.15%) As of 05/28/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
